Enliven Therapeutics CSO Joseph Lyssikatos Disposes of $535K in Shares Amid Promising CML Trial Data
Joseph P. Lyssikatos, Chief Scientific Officer at Enliven Therapeutics, executed stock sales totaling $535,098 through a pre-set trading plan, amidst the company's strong share performance and encouraging clinical trial updates for its chronic myeloid leukemia treatment. These transactions, reported in a recent SEC filing, reflect ongoing insider a…